JP2004521107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521107A5 JP2004521107A5 JP2002557974A JP2002557974A JP2004521107A5 JP 2004521107 A5 JP2004521107 A5 JP 2004521107A5 JP 2002557974 A JP2002557974 A JP 2002557974A JP 2002557974 A JP2002557974 A JP 2002557974A JP 2004521107 A5 JP2004521107 A5 JP 2004521107A5
- Authority
- JP
- Japan
- Prior art keywords
- naphthyl
- substituted
- phenyl
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 70
- 125000000217 alkyl group Chemical group 0.000 claims 52
- 125000000753 cycloalkyl group Chemical group 0.000 claims 35
- 125000001624 naphthyl group Chemical group 0.000 claims 24
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 21
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000003884 phenylalkyl group Chemical group 0.000 claims 10
- 210000000056 organ Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- -1 2-benzoxazolyl Chemical group 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 150000001975 deuterium Chemical group 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 125000004970 halomethyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/765,105 US7053056B2 (en) | 1998-07-02 | 2001-01-16 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| PCT/US2002/001538 WO2002057298A2 (en) | 2001-01-16 | 2002-01-16 | C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521107A JP2004521107A (ja) | 2004-07-15 |
| JP2004521107A5 true JP2004521107A5 (https=) | 2005-12-22 |
Family
ID=25072661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557974A Pending JP2004521107A (ja) | 2001-01-16 | 2002-01-16 | ＩＣＥ／ｃｅｄ−３ファミリーのシステインプロテアーゼのインヒビターとしての、Ｃ末端修飾されたオキサミルジペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7053056B2 (https=) |
| EP (1) | EP1351975A2 (https=) |
| JP (1) | JP2004521107A (https=) |
| CN (1) | CN1283656C (https=) |
| CA (1) | CA2433879A1 (https=) |
| WO (1) | WO2002057298A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| US7652153B2 (en) | 2004-02-27 | 2010-01-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| CN103951583B (zh) * | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| AU2009292959B2 (en) | 2008-09-19 | 2016-02-25 | Henry Ford Health System | Methods, systems, and compositions for calpain inhibition |
| WO2012021800A2 (en) * | 2010-08-13 | 2012-02-16 | Banyan Biomarkers | Caspase inhibitors as therapeutics for neural and organ injury and imaging |
| US9539050B2 (en) * | 2011-04-12 | 2017-01-10 | Covidien Lp | System and method for process monitoring and intelligent shut-off |
| JP2017515854A (ja) | 2014-05-12 | 2017-06-15 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤による慢性肝疾患の合併症の治療 |
| PT3204352T (pt) | 2014-10-06 | 2020-09-23 | Cortexyme Inc | Inibidores de lisina-gingipaína |
| WO2016144830A1 (en) | 2015-03-06 | 2016-09-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| CA3004095A1 (en) | 2015-11-09 | 2017-05-18 | Cortexyme, Inc. | Inhibitors of arginine gingipain |
| CA3010286A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| ES2992410T3 (es) | 2016-09-16 | 2024-12-12 | Lighthouse Pharmaceuticals Inc | Inhibidores cetónicos de la lisina gingipaína |
| RU2019113150A (ru) | 2016-10-05 | 2020-11-06 | Новартис Аг | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
| CA2122227A1 (en) | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
| US5869519A (en) * | 1996-12-16 | 1999-02-09 | Idun Pharmaceuticals, Inc. | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| AU738048B2 (en) | 1996-09-12 | 2001-09-06 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors |
| US5968927A (en) * | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US5877197A (en) * | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| FR2766188B1 (fr) | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| US6515173B1 (en) | 2000-01-13 | 2003-02-04 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
| EP1278737B1 (en) | 2000-04-24 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
-
2001
- 2001-01-16 US US09/765,105 patent/US7053056B2/en not_active Expired - Lifetime
-
2002
- 2002-01-16 CN CNB028052781A patent/CN1283656C/zh not_active Expired - Fee Related
- 2002-01-16 WO PCT/US2002/001538 patent/WO2002057298A2/en not_active Ceased
- 2002-01-16 JP JP2002557974A patent/JP2004521107A/ja active Pending
- 2002-01-16 EP EP02705856A patent/EP1351975A2/en not_active Withdrawn
- 2002-01-16 CA CA002433879A patent/CA2433879A1/en not_active Abandoned
-
2004
- 2004-08-25 US US10/926,800 patent/US7183260B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002519406A5 (https=) | ||
| JP2002527504A5 (https=) | ||
| JP2004521107A5 (https=) | ||
| RU2203897C2 (ru) | Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство | |
| CA2641880C (en) | Treatment of duchenne muscular dystrophy | |
| JP2017533922A5 (https=) | ||
| JP2010111691A5 (https=) | ||
| JP2008508360A5 (https=) | ||
| CN103561744A (zh) | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮在治疗免疫相关性和炎症性疾病中的用途 | |
| JP2007517059A (ja) | 中枢神経系障害治療用の免疫調節化合物 | |
| RU2009118489A (ru) | Органические соединения | |
| JP2002536329A5 (https=) | ||
| RU98115659A (ru) | Сульфированные аминокислотные производные и содержащие их ингибиторы металлопротеиназ | |
| AU2008257428A1 (en) | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | |
| RU2007130802A (ru) | Пуриновые производные в качестве агонистов рецептора а2а | |
| JP2006510606A5 (https=) | ||
| PH26920A (en) | Medicaments for the treatment of cerebral apoplexy | |
| AU2005314252B2 (en) | Compounds and methods for treating hemorrhagic fever viruses | |
| CA2750123A1 (en) | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis | |
| JP2007537299A5 (https=) | ||
| JP2622442B2 (ja) | 臓器用保護剤 | |
| RU2009148507A (ru) | Производное тетрагидроизохинолин-1-она или его соль | |
| EP0966283B1 (en) | Pharmaceutical products for curing and preventing diseases resulting from the damaging of the vascular endothelial cells | |
| JP2005522492A5 (https=) | ||
| RU2005105058A (ru) | Новые производные арилимидазола, их препараты и их терапевтические применения |